Education
About Us
Working with TipRanks
Follow Us
S2Medical AB Class B (DE:S21)
FRANKFURT:S21
S21 Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EST
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€805.00K
Enterprise Value$6.66M
Total Cash (Recent Filing)€1.29M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta13.19
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding898,657,040
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.93
Price to Sales (P/S)0.64
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€5.54M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetMinimal debt provides durable financial flexibility for a small medical-instruments company. Low leverage reduces refinancing and interest-risk, enabling management to prioritize product development, regulatory compliance and selective investment during downturns without immediate external funding needs.
Improving Operating Cash Flow TrajectoryTransitioning from multi-year operating cash burn to positive OCF signals structural improvement in core business economics. Even if 2025 OCF weakened versus 2024, sustained positive operational cash generation supports working capital, reduces dependency on financing, and underpins longer-term viability.
Demonstrated Ability To Scale Revenue And MarginsA materially profitable 2024 shows the company can achieve product-market fit and margin expansion when conditions align. This operational proof point indicates the business model can scale and generate returns if revenue recovery and cost control are sustained, guiding long-term strategy.
Bears Say
Highly Volatile Profitability And Margin SwingsLarge, rapid swings in revenue and margins indicate the company lacks stable, diversified revenue streams or consistent pricing power. Persistent volatility undermines planning, erodes equity in downturns, and makes sustaining R&D, regulatory and commercial investments risky over the next several quarters.
Weak Free Cash Flow And Inconsistent Cash ConversionNear-zero FCF despite positive OCF constrains the firm’s ability to fund capex, product launches, or absorb shocks without external capital. Inconsistent cash conversion reduces runway and increases dependence on financing or equity raises, creating structural execution risk over a 2–6 month horizon.
Fluctuating Equity And Modest Asset BaseMeaningful swings in shareholders’ equity point to an unstable capital base that can be rapidly eroded by losses. For a small medical-instruments firm with modest assets, this volatility limits strategic optionality, weakens bargaining with suppliers/customers, and raises the probability of future dilution or capital raises.
S21 FAQ
What was S2Medical AB Class B’s price range in the past 12 months?
Currently, no data Available
What is S2Medical AB Class B’s market cap?
S2Medical AB Class B’s market cap is €805.00K.
When is S2Medical AB Class B’s upcoming earnings report date?
S2Medical AB Class B’s upcoming earnings report date is Aug 21, 2026 which is in 165 days.
How were S2Medical AB Class B’s earnings last quarter?
S2Medical AB Class B released its earnings results on Feb 20, 2026. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is S2Medical AB Class B overvalued?
According to Wall Street analysts S2Medical AB Class B’s price is currently Overvalued.
Does S2Medical AB Class B pay dividends?
S2Medical AB Class B does not currently pay dividends.
What is S2Medical AB Class B’s EPS estimate?
S2Medical AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does S2Medical AB Class B have?
S2Medical AB Class B has 898,657,040 shares outstanding.
What happened to S2Medical AB Class B’s price movement after its last earnings report?
S2Medical AB Class B reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 100%.
Which hedge fund is a major shareholder of S2Medical AB Class B?
Currently, no hedge funds are holding shares in DE:S21
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
S2Medical AB Class B
S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds. It offers INSTAQRETT, a sterile single use mechanical debridement tool; EPIPROTECT SafeStop for blood stilling; Instagraft, a single-use medical device for the treatment of chronic and complicated wounds; EPIPROTECT tissue substitutes; and washable, waterproof, and self-adhesive bandages under the INSTABIND brand name. The company also distributes Silverlon dressings that deliver silver ions into the wound. In addition, it operates wound healing center under the S2Clinic name. The company was founded in 2013 and is headquartered in Linköping, Sweden.